Icosapent Ethyl
Generic name: Pronounced as (eye koe' sa pent eth il)
Medical Content Reviewed By HelloPharmacist Staff
Last Revised - 05/15/2020
On this page
- Why is this medication prescribed?
- How should this medicine be used?
- Other uses for this medicine
- What special precautions should I follow?
- What special dietary instructions should I follow?
- What should I do if I forget a dose?
- What side effects can this medication cause?
- What should I know about STORAGE and DISPOSAL of this medication?
- What should I do in case of OVERDOSE?
- What OTHER INFORMATION should I know?
- Drug interactions
Why is this medication prescribed?
Icosapent ethyl is used together with lifestyle changes (diet, weight loss, exercise) to reduce the amount of triglycerides (a fat-like substance) in the blood. It is also used along with cholesterol-lowering medications (statins) to decrease the risk of a heart attack, a stroke, or other heart problems that require hospitalization in certain adults with high triglyceride levels and heart disease or diabetes with 2 or more other heart disease risk factors. Icosapent ethyl is in a class of medications called antilipemic or lipid-regulating agents. Icosapent ethyl may work by decreasing the amount of triglycerides and other fats made in the liver.
How should this medicine be used?
Icosapent ethyl comes as a liquid-filled gel capsule to take by mouth. It is usually taken with food two times a day. Take icosapent ethyl at around the same times every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take icosapent ethyl exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Swallow the capsules whole; do not split, chew, crush, or dissolve them.
Ask your pharmacist or doctor for a copy of the manufacturer's information for the patient.
Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before taking icosapent ethyl,
-
tell your doctor and pharmacist if you are allergic to icosapent ethyl; fish, including shellfish (clams, scallops, shrimp, lobster, crayfish, crab, oyster, mussels, others); any other medications; or any of the ingredients in icosapent ethyl capsules. Ask your pharmacist or check the patient information for a list of the ingredients.
-
tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven); antiplatelet medications such as cilostazol (Pletal), clopidogrel (Plavix), dipyridamole (Persantine, in Aggrenox), prasugrel (Effient), and ticlopidine (Ticlid); aspirin or aspirin-containing products; beta-blockers such as atenolol (Tenormin), labetalol (Normodyne), metoprolol (Lopressor, Toprol XL), nadolol (Corgard), and propranolol (Inderal); diuretics ('water pills'); estrogen-containing contraceptives (birth control pills, patches, rings, and injections); or estrogen replacement therapy. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
-
tell your doctor if you have or have ever had diabetes, irregular heartbeat or heart rhythm problems, or heart, liver, thyroid, or pancreatic disease.
-
tell your doctor if you are pregnant, plan to become pregnant, or are breast-feeding. If you become pregnant while taking icosapent ethyl, call your doctor.
What special dietary instructions should I follow?
Eat a low-fat, low-cholesterol diet. Be sure to follow all exercise and dietary recommendations made by your doctor or dietitian. You can also visit the National Cholesterol Education Program (NCEP) website for additional dietary information at http://www.nhlbi.nih.gov/health/public/heart/chol/chol_tlc.pdf.
What should I do if I forget a dose?
Take the missed dose as soon as you remember it. However, if you miss 1 day of icosapent ethyl, continue your regular dosing schedule. Do not take a double dose to make up for a dose missed on the previous day.
What side effects can this medication cause?
-
Icosapent ethyl may cause side effects. Tell your doctor if this symptom is severe or does not go away:
-
muscle or joint pain
-
constipation
-
swelling of legs, ankles, or feet
-
-
Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:
-
fast and irregular heartbeat, lightheadedness, dizziness, shortness of breath, chest discomfort, or feeling faint
-
pain, redness, or swelling in the joints, especially in the big toe
-
rash, hives, itching, or difficulty breathing or swallowing
-
unusual bruising or bleeding
-
-
Icosapent ethyl may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.
-
If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).
What should I know about STORAGE and DISPOSAL of this medication?
Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).
It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org
Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.
What should I do in case of OVERDOSE?
In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.
What OTHER INFORMATION should I know?
Keep all appointments with your doctor and the laboratory. Your doctor may order certain lab tests to check your body's response to icosapent ethyl.
Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.
It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.
Drug interactions
Drug | Interaction |
---|---|
Anagrelide | Anagrelide Anagrelide may increase the antiplatelet activities of Icosapent ethyl. |
Cilostazol | Cilostazol Cilostazol may increase the antiplatelet activities of Icosapent ethyl. |
Clopidogrel | Clopidogrel Clopidogrel may increase the antiplatelet activities of Icosapent ethyl. |
Olsalazine | Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Icosapent ethyl. |
Tacrolimus | Tacrolimus The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Tacrolimus. |
Interferon Beta-1b Injection | Interferon Beta-1b Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon beta-1b. |
Interferon Gamma-1b Injection | Interferon Gamma-1b Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon gamma-1b. |
Zidovudine Injection | Zidovudine Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Zidovudine. |
Altretamine | Altretamine The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Icosapent ethyl. |
Enoxaparin Injection | Enoxaparin Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Enoxaparin. |
Meloxicam | Meloxicam The risk or severity of bleeding can be increased when Meloxicam is combined with Icosapent ethyl. |
Temozolomide | Temozolomide The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Temozolomide. |
Linezolid | Linezolid The risk or severity of bleeding and hemorrhage can be increased when Linezolid is combined with Icosapent ethyl. |
Pentosan Polysulfate | Pentosan Polysulfate The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Icosapent ethyl. |
Choline Magnesium Trisalicylate | Choline Magnesium Trisalicylate The risk or severity of bleeding can be increased when Choline magnesium trisalicylate is combined with Icosapent ethyl. |
Sirolimus | Sirolimus The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Sirolimus. |
Epirubicin | Epirubicin The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Epirubicin. |
Escitalopram | Escitalopram The risk or severity of bleeding can be increased when Escitalopram is combined with Icosapent ethyl. |
Duloxetine | Duloxetine Duloxetine may increase the antiplatelet activities of Icosapent ethyl. |
Dextroamphetamine | Dextroamphetamine The risk or severity of bleeding and hemorrhage can be increased when Amphetamine is combined with Icosapent ethyl. |
Peginterferon Alfa-2a Injection | Peginterferon Alfa-2a Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Peginterferon alfa-2a. |
Peginterferon Alfa-2b (PEG-Intron) | Peginterferon Alfa-2b (PEG-Intron) The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Peginterferon alfa-2b. |
Isocarboxazid | Isocarboxazid The risk or severity of bleeding and hemorrhage can be increased when Isocarboxazid is combined with Icosapent ethyl. |
Tipranavir | Tipranavir Tipranavir may increase the antiplatelet activities of Icosapent ethyl. |
Rasagiline | Rasagiline The risk or severity of bleeding and hemorrhage can be increased when Rasagiline is combined with Icosapent ethyl. |
Imatinib | Imatinib The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Imatinib. |
Bortezomib | Bortezomib The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Bortezomib. |
Clofarabine Injection | Clofarabine Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Clofarabine. |
Oxaliplatin Injection | Oxaliplatin Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Oxaliplatin. |
Rituximab Injection | Rituximab Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Rituximab. |
Bismuth Subsalicylate | Bismuth Subsalicylate The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Bismuth subsalicylate. |
Pemetrexed Injection | Pemetrexed Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Pemetrexed. |
Vorinostat | Vorinostat The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Vorinostat. |
Sorafenib | Sorafenib The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Sorafenib. |
Dasatinib | Dasatinib Dasatinib may increase the anticoagulant activities of Icosapent ethyl. |
Omega-3 Fatty Acids | Omega-3 Fatty Acids Omega-3 fatty acids may increase the antiplatelet activities of Icosapent ethyl. |
Azacitidine Injection | Azacitidine Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Azacitidine. |
Temsirolimus | Temsirolimus The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Temsirolimus. |
Nelarabine Injection | Nelarabine Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Nelarabine. |
Lenalidomide | Lenalidomide The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Lenalidomide. |
Nilotinib | Nilotinib The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Nilotinib. |
Bexarotene | Bexarotene The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Bexarotene. |
Chloramphenicol Injection | Chloramphenicol Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Chloramphenicol. |
Decitabine Injection | Decitabine Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Decitabine. |
Arsenic Trioxide Injection | Arsenic Trioxide Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Arsenic trioxide. |
Mitoxantrone Injection | Mitoxantrone Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Mitoxantrone. |
Desvenlafaxine | Desvenlafaxine Desvenlafaxine may increase the antiplatelet activities of Icosapent ethyl. |
Bendamustine Injection | Bendamustine Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Bendamustine. |
Ixabepilone Injection | Ixabepilone Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ixabepilone. |
Irinotecan Injection | Irinotecan Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Irinotecan. |
Alemtuzumab Injection (Chronic Lymphocytic Leukemia) | Alemtuzumab Injection (Chronic Lymphocytic Leukemia) The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Alemtuzumab. |
Dexrazoxane Injection | Dexrazoxane Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dexrazoxane. |
Ibritumomab Injection | Ibritumomab Injection The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Ibritumomab tiuxetan. |
Milnacipran | Milnacipran Milnacipran may increase the antiplatelet activities of Icosapent ethyl. |
Prasugrel | Prasugrel The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Prasugrel. |
Everolimus | Everolimus The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Everolimus. |
Topotecan | Topotecan The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Topotecan. |
Dabigatran | Dabigatran The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dabigatran. |
Eribulin Injection | Eribulin Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Eribulin. |
Cabazitaxel Injection | Cabazitaxel Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cabazitaxel. |
Denileukin Diftitox Injection | Denileukin Diftitox Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Aldesleukin. |
Busulfan Injection | Busulfan Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Busulfan. |
Cyclophosphamide Injection | Cyclophosphamide Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cyclophosphamide. |
Rivaroxaban | Rivaroxaban Icosapent ethyl may increase the anticoagulant activities of Rivaroxaban. |
Ticagrelor | Ticagrelor The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ticagrelor. |
Ruxolitinib | Ruxolitinib The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ruxolitinib. |
Melphalan Injection | Melphalan Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Melphalan. |
Fondaparinux Injection | Fondaparinux Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Fondaparinux. |
Carfilzomib Injection | Carfilzomib Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Carfilzomib. |
Iloprost | Iloprost The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Iloprost. |
Bosutinib | Bosutinib The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Bosutinib. |
Tofacitinib | Tofacitinib The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Tofacitinib. |
Ponatinib | Ponatinib The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ponatinib. |
Pomalidomide | Pomalidomide The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Pomalidomide. |
Ado-trastuzumab Emtansine Injection | Ado-trastuzumab Emtansine Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Trastuzumab emtansine. |
Apixaban | Apixaban The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Apixaban. |
Levomilnacipran | Levomilnacipran Levomilnacipran may increase the antiplatelet activities of Icosapent ethyl. |
Ibrutinib | Ibrutinib Icosapent ethyl may increase the antiplatelet activities of Ibrutinib. |
Ketorolac Injection | Ketorolac Injection The risk or severity of bleeding can be increased when Ketorolac is combined with Icosapent ethyl. |
Obinutuzumab Injection | Obinutuzumab Injection The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Obinutuzumab. |
Belinostat Injection | Belinostat Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Belinostat. |
Vorapaxar | Vorapaxar The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Vorapaxar. |
Edoxaban | Edoxaban The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Edoxaban. |
Peginterferon Beta-1a Injection | Peginterferon Beta-1a Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Peginterferon beta-1a. |
Olaparib | Olaparib The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Olaparib. |
Blinatumomab Injection | Blinatumomab Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Blinatumomab. |
Palbociclib | Palbociclib The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Palbociclib. |
Dinutuximab Injection | Dinutuximab Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dinutuximab. |
Deoxycholic Acid Injection | Deoxycholic Acid Injection The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Deoxycholic acid. |
Trabectedin Injection | Trabectedin Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Trabectedin. |
Defibrotide Injection | Defibrotide Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Defibrotide. |
Obeticholic Acid | Obeticholic Acid The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Obeticholic acid. |
Safinamide | Safinamide The risk or severity of bleeding and hemorrhage can be increased when Safinamide is combined with Icosapent ethyl. |
Betrixaban | Betrixaban The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Betrixaban. |
Gemtuzumab Ozogamicin Injection | Gemtuzumab Ozogamicin Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Gemtuzumab ozogamicin. |
Penicillamine | Penicillamine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Penicillamine. |
Paclitaxel (with albumin) Injection | Paclitaxel (with albumin) Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Paclitaxel. |
Caplacizumab-yhdp Injection | Caplacizumab-yhdp Injection Caplacizumab may increase the antiplatelet activities of Icosapent ethyl. |
Cladribine | Cladribine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cladribine. |
Fenoprofen | Fenoprofen The risk or severity of bleeding can be increased when Fenoprofen is combined with Icosapent ethyl. |
Indomethacin | Indomethacin The risk or severity of bleeding can be increased when Indomethacin is combined with Icosapent ethyl. |
Mefenamic Acid | Mefenamic Acid The risk or severity of bleeding can be increased when Mefenamic acid is combined with Icosapent ethyl. |
Naproxen | Naproxen The risk or severity of bleeding can be increased when Naproxen is combined with Icosapent ethyl. |
Tolmetin | Tolmetin The risk or severity of bleeding can be increased when Tolmetin is combined with Icosapent ethyl. |
Sulindac | Sulindac The risk or severity of bleeding can be increased when Sulindac is combined with Icosapent ethyl. |
Trazodone | Trazodone The risk or severity of bleeding can be increased when Trazodone is combined with Icosapent ethyl. |
Hydroxyurea | Hydroxyurea The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Hydroxyurea. |
Floxuridine | Floxuridine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Floxuridine. |
Methotrexate Injection | Methotrexate Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Methotrexate. |
Carmustine | Carmustine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Carmustine. |
Tranylcypromine | Tranylcypromine The risk or severity of bleeding and hemorrhage can be increased when Tranylcypromine is combined with Icosapent ethyl. |
Phenelzine | Phenelzine The risk or severity of bleeding and hemorrhage can be increased when Phenelzine is combined with Icosapent ethyl. |
Procarbazine | Procarbazine The risk or severity of bleeding and hemorrhage can be increased when Procarbazine is combined with Icosapent ethyl. |
Thioguanine | Thioguanine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Tioguanine. |
Ibuprofen | Ibuprofen The risk or severity of bleeding can be increased when Ibuprofen is combined with Icosapent ethyl. |
Sulfasalazine | Sulfasalazine The risk or severity of bleeding can be increased when Sulfasalazine is combined with Icosapent ethyl. |
Lomustine | Lomustine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Lomustine. |
Doxorubicin | Doxorubicin The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Doxorubicin. |
Cytarabine | Cytarabine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cytarabine. |
Mechlorethamine | Mechlorethamine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Mechlorethamine. |
Dactinomycin | Dactinomycin The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dactinomycin. |
Carbamazepine | Carbamazepine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Carbamazepine. |
Warfarin | Warfarin The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Warfarin. |
Meclofenamate | Meclofenamate The risk or severity of bleeding can be increased when Meclofenamic acid is combined with Icosapent ethyl. |
Daunorubicin | Daunorubicin The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Daunorubicin. |
Sulfinpyrazone | Sulfinpyrazone Sulfinpyrazone may increase the antiplatelet activities of Icosapent ethyl. |
Mitomycin | Mitomycin The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Mitomycin. |
Methimazole | Methimazole The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Methimazole. |
Propylthiouracil | Propylthiouracil The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Propylthiouracil. |
Mercaptopurine | Mercaptopurine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Mercaptopurine. |
Fluorouracil Injection | Fluorouracil Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Fluorouracil. |
Dacarbazine | Dacarbazine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dacarbazine. |
Thiotepa Injection | Thiotepa Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Thiotepa. |
Dipyridamole | Dipyridamole The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dipyridamole. |
Vinblastine | Vinblastine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Vinblastine. |
Aspirin | Aspirin Acetylsalicylic acid may increase the antiplatelet activities of Icosapent ethyl. |
Salsalate | Salsalate The risk or severity of bleeding can be increased when Salsalate is combined with Icosapent ethyl. |
Chlorambucil | Chlorambucil The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Chlorambucil. |
Cisplatin Injection | Cisplatin Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cisplatin. |
Diflunisal | Diflunisal The risk or severity of bleeding can be increased when Diflunisal is combined with Icosapent ethyl. |
Piroxicam | Piroxicam The risk or severity of bleeding can be increased when Piroxicam is combined with Icosapent ethyl. |
Streptozocin | Streptozocin The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Streptozocin. |
Etoposide | Etoposide The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Etoposide. |
Pentoxifylline | Pentoxifylline Pentoxifylline may increase the antiplatelet activities of Icosapent ethyl. |
Ketoprofen | Ketoprofen The risk or severity of bleeding can be increased when Ketoprofen is combined with Icosapent ethyl. |
Flurbiprofen | Flurbiprofen The risk or severity of bleeding can be increased when Flurbiprofen is combined with Icosapent ethyl. |
Mesalamine | Mesalamine The risk or severity of bleeding can be increased when Mesalazine is combined with Icosapent ethyl. |
Diclofenac | Diclofenac The risk or severity of bleeding can be increased when Diclofenac is combined with Icosapent ethyl. |
Fluoxetine | Fluoxetine The risk or severity of hemorrhage can be increased when Fluoxetine is combined with Icosapent ethyl. |
Interferon Alfa-2b Injection | Interferon Alfa-2b Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Interferon alfa-2b. |
Idarubicin | Idarubicin The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Idarubicin. |
Fludarabine Injection | Fludarabine Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Fludarabine. |
Pentostatin Injection | Pentostatin Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Pentostatin. |
Etodolac | Etodolac The risk or severity of bleeding can be increased when Etodolac is combined with Icosapent ethyl. |
Nabumetone | Nabumetone The risk or severity of bleeding can be increased when Nabumetone is combined with Icosapent ethyl. |
Teniposide Injection | Teniposide Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Teniposide. |
Oxaprozin | Oxaprozin The risk or severity of bleeding can be increased when Oxaprozin is combined with Icosapent ethyl. |
Venlafaxine | Venlafaxine Venlafaxine may increase the antiplatelet activities of Icosapent ethyl. |
Fluvoxamine | Fluvoxamine The risk or severity of hemorrhage can be increased when Fluvoxamine is combined with Icosapent ethyl. |
Nefazodone | Nefazodone The risk or severity of hemorrhage can be increased when Nefazodone is combined with Icosapent ethyl. |
Vinorelbine Injection | Vinorelbine Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Vinorelbine. |
Carboplatin Injection | Carboplatin Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Carboplatin. |
Ifosfamide Injection | Ifosfamide Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Ifosfamide. |
Ticlopidine | Ticlopidine Ticlopidine may increase the antiplatelet activities of Icosapent ethyl. |
Dalteparin Injection | Dalteparin Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Dalteparin. |
Gemcitabine Injection | Gemcitabine Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Gemcitabine. |
Docetaxel Injection | Docetaxel Injection The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Docetaxel. |
Selegiline | Selegiline The risk or severity of bleeding and hemorrhage can be increased when Selegiline is combined with Icosapent ethyl. |
Sertraline | Sertraline The risk or severity of bleeding can be increased when Sertraline is combined with Icosapent ethyl. |
Paroxetine | Paroxetine The risk or severity of hemorrhage can be increased when Paroxetine is combined with Icosapent ethyl. |
Citalopram | Citalopram The risk or severity of hemorrhage can be increased when Citalopram is combined with Icosapent ethyl. |
Capecitabine | Capecitabine The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Capecitabine. |
Celecoxib | Celecoxib The risk or severity of bleeding can be increased when Celecoxib is combined with Icosapent ethyl. |
Thalidomide | Thalidomide The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Thalidomide. |
Balsalazide | Balsalazide The risk or severity of bleeding can be increased when Balsalazide is combined with Icosapent ethyl. |
Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists